Drugs / BVAC-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03425773 | Feb 2018 → May 2019 | gastric neoplasm | Cellid Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVAC-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03425773 ↗ |
| Modality | Vaccine | “BVAC-B is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell.” NCT03425773 ↗ |
| Route | Intravenous | “BVAC-B IV injection at 0, 4, 8, 12nd weeks.” NCT03425773 ↗ |